Abstract 4619
Background
Inflammation impacts each step of tumorigenesis, including tumor initiation, promotion and metastatic progression. Biomarkers including the neutrophil, lymphocyte and platelet count, as well as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) are indices of inflammation. The aim of the present study was to assess the blood the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) as a prognostic factors in male breast cancer patients (BC).
Methods
A the retrospective analysis of 38 male BC patients who were treated at COI (Gliwice, Poland) between January 2005 and December 2018 was performed. Based on the cut-off values determined, the NLR was considered as ‘elevated’ at > 2.65, the MLR value was ‘elevated’ at > 0.28 and the PLR was considered ‘elevated’ at > 190.9. The prognostic value (OS) of the pre-treatment PLR, NLR and MLR was assessed by univariate analysis.
Results
There was observed tendency to worse 5-year OS in male BC patients with lymph node metastases (N+) (43.5% vs. 73.9%, p = 0.171); higher tumor size (T4 vs. T1) (42% vs.85.79%, p = 0.128); negative steroid receptor status (PR-) (28.6% vs. 65.6%, p = 0.109). Patients with cancer family history had significantly better 5-year OS than patients without cancer family history (86.3% vs.35.0%, p = 0.004).Younger male BC patients (age ≤53 years) had better 5 year OS in comparison to patients over 53 years (88.9% vs. 43.1%, p = 0.014).The 5-year OS was lower in patients with lower lymphocyte value ≤1.52 (24.0% vs. 67.4%, p = 0.010). There was reported tendency to the worse 5-year OS in patients with higher PLT value (PLT>193 x 10^3) (47.3% vs. 78.8%, p = 0.157). The 5-year OS was lower in the NLR >2.75 compared with that in the NLR≤2.75 group (29.6% vs. 64.4%, p = 0.031). Similarly, a worse OS rate was associated with an elevated PLR (>114.5) (34.4% vs.77.5%, p = 0.021). There was detected tendency to worse OS in group with lower MLR level (≤3.23) (39.5% vs. 71.9%, p = 0.155).
Conclusions
The present results revealed that an elevated NLR (>2.75) and PLR (>114.5) are associated with poor OS in male breast cancer patients. In contrary, the elevated MLR affected better OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2607 - Single cycle induction treatment with Cisplatin/Docetaxel plus Durvalumab/Tremelimumab in Stage III-IVB head and neck squamous cell cancer (CheckRad-CD8 trial)
Presenter: Markus Hecht
Session: Poster Display session 3
Resources:
Abstract
1388 - Radiotherapy plus cisplatin (CDDP) or cetuximab (C225) in human papilloma-virus (HPV)-associated oropharyngeal cancer (OPC)? A dillema finally resolved. An updated meta-analysis.
Presenter: Petar Suton
Session: Poster Display session 3
Resources:
Abstract
1478 - Treatment outcomes of head and neck cancer patients 70 years and older receiving different chemo-radiation combinations.
Presenter: Majd Issa
Session: Poster Display session 3
Resources:
Abstract
3985 - Brachytherapy and non-cancer mortality in patients with oral cavity and oropharynx SCCs
Presenter: Jovian Yu
Session: Poster Display session 3
Resources:
Abstract
4036 - Final results of a phase II study of induction chemotherapy (CT) with paclitaxel (PTX) and panitumumab (P) followed by radiotherapy (RT) and P in patients (pts) with locally advanced head and neck cancer (LAHNC) no candidates to platinum: study PANTERA
Presenter: Javier Martinez Trufero
Session: Poster Display session 3
Resources:
Abstract
4779 - Window of Opportunity for Durvalumab (MEDI4736) plus Metformin Trial in Squamous Cell Carcinoma of the Head and Neck (SCCHN): interim safety analysis
Presenter: Tony Richa
Session: Poster Display session 3
Resources:
Abstract
2757 - Severe Oral Mucositis (SOM) Mitigation by Genetically Modified Lactococcus Lactis Bacteria (LLB) Producing Human Trefoil Factor 1 (hTFF1; AG013) in Patients Being Treated With Concomitant Chemoradiation (CRT) for Oral and Oropharyngeal Cancers (OCOPC)
Presenter: Suraj Singh
Session: Poster Display session 3
Resources:
Abstract
5559 - Transcriptome signatures of treatment responses in a preoperative window of opportunity trial of nivolumab and tadalafil in resectable squamous cell carcinoma of the head and neck
Presenter: Sanket Shukla
Session: Poster Display session 3
Resources:
Abstract
3263 - Risk and Impact of Renal Impairment of Locally Advanced Head and Neck Squamous Cell Carcinoma Patients Who Received Chemoradiotherapy with Cisplatin
Presenter: Thana Patimarattananan
Session: Poster Display session 3
Resources:
Abstract
3128 - Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center
Presenter: Sumita Trivedi
Session: Poster Display session 3
Resources:
Abstract